Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 602 of 6351
-
Reading RNA: a new clue to solve genetic mysteries?
Knowledge-focused Recruiting nowThe goal of this observational study is to see if ribonucleic acid (RNA) sequencing can improve the diagnostic yield and accuracy of genetic testing compared to gene sequencing alone. Participants will be asked to share their medical history and prior genetic testing results, and…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
New pill plus immunotherapy takes on tough melanoma
Disease control Recruiting nowThe goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during which melanoma does not grow or spread after starting treatment with LNS8801? Re…
Phase 2/3 • Sponsor: Linnaeus Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a common blood pressure drug help kids with type 1 diabetes keep making insulin?
Disease control Recruiting nowThe objective of this trial is first to evaluate safety and then the effect on preservation of residual beta cell function also clinical efficacy by treatment with Verapamil in children with recent onset Type 1 diabetes. Patients are included with the following inclusion criteri…
Phase 1/2 • Sponsor: Johnny Ludvigsson • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New antibody drug targets skin scarring in transplant survivors
Disease control Recruiting nowThis phase II trial tests how well axatilimab works in treating patients with thickening or hardening (sclerosis) of the skin related to chronic graft-versus-host disease after a donor stem cell transplant. Chronic graft-versus-host disease (cGVHD) remains a major complication of…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cancer gel shows promise for rare urinary tract tumors
Disease control Recruiting nowThis study will evaluate the efficacy and safety of UGN-104, a new formulation of UGN-101 (approved in the United States and Israel as JELMYTO \[mitomycin\] for pyelocalyceal solution), instilled in the upper urinary tract (UUT) of patients with low-grade upper tract urothelial c…
Phase 3 • Sponsor: UroGen Pharma Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a simple wash of local anesthetic cut Post-Surgery pain and opioid use?
Symptom relief CompletedThe goal of this clinical trial is to determine the safety and efficacy of combined intraperitoneal local anesthetic instillation and port-site infiltration using lidocaine and bupivacaine in adults aged 18 to 60 undergoing elective laparoscopic abdominal surgeries (such as lapar…
Sponsor: Misr University for Science and Technology • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
New RSV vaccine trial offers hope for transplant patients
Vaccine OngoingThis study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Aug 01, 2026 00:00 UTC
-
New combo targets liver tumors in hard-to-treat colorectal cancer
Disease control Recruiting nowThe goal of this clinical trial is to learn if using a liver-directed therapy with high dose chemotherapy followed by approved cancer treatment to treat patients with colorectal cancer that has spread to the liver is safe and tolerable. The clinical trial will also learn if the l…
Phase 2 • Sponsor: Delcath Systems Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Baby's own cord tissue used to patch spinal defect in promising new trial
Disease control Recruiting nowThe purpose of this study is to determine the impact of an autologous umbilical cord patch for dural closure on the repair of open neural tube defect. The outcomes will evaluate successful defect closure, creation of a more capacious spinal canal, and reduction in inflammatory ti…
Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jun 26, 2026 15:32 UTC
-
Triple therapy shows promise for untreatable liver cancer
Disease control OngoingThis is a Phase II, single-arm, multicentre study, assessing the efficacy and safety of durvalumab and tremelimumab with lenvatinib in participants with unresectable HCC.
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New shot could clear eczema in teens – trial underway
Disease control Recruiting nowThe primary objective of the study was to evaluate the efficacy of 611 in Chinese Adolescents with moderate to severe atopic dermatitis.
Phase 3 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for advanced breast cancer: experimental drug combo enters final testing
Disease control Recruiting nowThe purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on …
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New MRI technique could help surgeons see and remove hidden brain tumor cells
Disease control Recruiting nowCurrent standard of care therapy and all FDA approved adjuvant therapy for glioblastoma continue to provide less than 12 months of progression free survival (PFS) and less than 24 months of overall survival (OS). There is an extreme need for any novel therapy against glioblastoma…
Phase 1 • Sponsor: University of California, Los Angeles • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Shocking discovery: nerve zaps may prevent bladder damage after spinal injury
Prevention Recruiting nowSuprasacral spinal cord injury (SCI) frequently leads to neurogenic detrusor overactivity (NDO), resulting in elevated bladder storage pressures, urinary incontinence, and an increased risk of upper urinary tract damage. Early regulation of bladder function is a key objective of …
Sponsor: Ankara City Hospital Bilkent • Aim: Prevention
Last updated Jun 27, 2026 08:11 UTC
-
Heart patients may ditch blood thinners after ablation, major trial investigates
Disease control Recruiting nowDIAMOND-AF is a multicenter, randomized, open-label trial evaluating whether discontinuing oral anticoagulation after successful atrial fibrillation ablation can reduce bleeding risk without increasing death or thromboembolism risks. Adults aged 18-80 years, 60-365 days post-abla…
Sponsor: Beijing Anzhen Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug duo takes on rare liver virus in head-to-head trial
Disease control OngoingA Study to Evaluate Tobevibart+Elebsiran versus Bulevirtide in Chronic HDV Infection
Phase 2 • Sponsor: Vir Biotechnology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
DMT for depression: scientists test if the psychedelic experience matters
Symptom relief Recruiting nowThe aim of this study is to elucidate if the anti-depressive effect of N,N-dimethyltryptamine (DMT) is based on a biological mechanisms including neuroplasticity and anti-inflammatory effect or due to the subjective psychedelic experience.
Sponsor: University Hospital, Basel, Switzerland • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Massive drug showdown: can a new pill beat river blindness for good?
Disease control Recruiting nowThis clinical trial compares two treatments - ivermectin and moxidectin - to learn which is better at reducing the proportion of people with onchocerciasis (river blindness) when given through mass drug administration (MDA) in Angola. Both drugs are approved by the United States …
Phase 4 • Sponsor: Kirby Institute • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New cell therapy hopes to tame tough autoimmune diseases
Disease control Recruiting nowThis study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), including LN and SLE-ITP, Sjogren's Syndrome, etc. Aproximately 18 patients aged 18-65 will receive a single infusion o…
Phase 1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New pill targets Hard-to-Treat cancers with rare TP53 mutation
Disease control Recruiting nowThis study is to evaluate the safety, tolerability, PK, and preliminary efficacy of NTS071 in adults with TP53 Y220C-mutated solid tumors.
Phase 1/2 • Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC